Abvc biopharma provides adhd phase ii part 2 clinical update

Fremont, ca, july 13, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced the enrollment progress in the phase ii part ii clinical study of the company's adhd medicine (abv-1505). since results on the first subject treated were reported on may 10, 2022, a total of 22 subjects have been enrolled in the study from a total of 32 subjects screened. one of the enrolled participants from the three arms completed the 8-week treatment per the study design.
ABVC Ratings Summary
ABVC Quant Ranking